Objectives of Work Package 5 objectives for today Information on centres of expertise for rare cancers WP leader: Sabine Siesling.

Slides:



Advertisements
Similar presentations
29/08/2003 Midterm Review Meeting Helsinki Midterm Review Meeting, Helsinki2 Overall Objective Research Infrastructure The establishment of.
Advertisements

EUROCHIP-3 WORK PACKAGES. MAIN WORK PACKAGES of EUROCHIP-3 Ahti Anttila Adherence to cervical screening in 5 Eastern EU countries Renée Otter Population-based.
EUROCHIP-3: WP-4 Publications Paolo Baili Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
¨ Dr Alain Garcia General Secretary of the Rare Diseases National Plan The second National Plan for Rare Diseases in France
High Resolution data for rare cancers Annalisa Trama Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (Italy ) WORKSHOP FOR A EUROPEAN HIGH RESOLUTION.
Engaging Patients and Other Stakeholders in Clinical Research
Dr Andrea Micheli Descriptive Epidemiology and Health Planning Unit Fondazione IRCCS “Istituto Nazionale dei Tumori” Milan Public Health Programme EUROPEAN.
EUROCHIP PILOT STUDIES. Collection of detailed clinical information for specific tumours Describing and comparing care in representative samples of cancer.
March 2002 Outcomes in thyroid cancer: what factors are important? Information Projects Team Outcomes in thyroid cancer: what factors are important? NYCRIS.
THE EUROCHIP PROJECTS Health Indicators for Health Indicators for Monitoring Cancer in Europe
The National Cancer Intelligence Network An overview Professor David Forman Professor of Cancer Epidemiology, University of Leeds NCIN – Lead for Information.
Guidance on Cancer Services Improving Outcomes for People with Skin Tumours including Melanoma NICE Stateholder Consultation version July 2005.
Purposes and uses of cancer registration E.E.U. Akang Department of Pathology University College Hospital Ibadan, Nigeria.
How are cancer statistics kept up to date?.  Example:  Dx stage II colon cancer  Cancer has metastasized to the liver – 2009  How does the.
Quality Cancer Data The Vital Role of Cancer Registrars in the Fight against Cancer Saves Lives.
EUROCHIP - EUROpean Cancer Health Indicators Project A project supported by the European Commission Andrea Micheli 1, Paolo Baili 1, Carmen Martinez 2,
Name Speaker This work is part of the Joint Action on Improving Quality in HIV Prevention (Quality Action), which has received funding from the European.
Information network on rare cancers RARECARENet Annalisa Trama, Gemma Gatta Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (Italy)
This document arises from the project InNerMeD-I-Network which has received funding from the European Union, in the framework of the Health Programme INHERITED.
Work Package 7 Information for patients with rare cancers WP leader: Francesco De Lorenzo.
SYNOPSIS OF THE PROTOCOL Title: Pregnancy Associated Breast Cancer (PABC); Prospective Data Registry in Saudi Arabia Sponsor: Oncology Department, King.
RARECARE project Cancer registries and rare cancers: quality of data, supplementary information RARECARE WP6, 3 rd meeting th National Institute of Public.
Criteria for Centres of Expertise for Rare Diseases in the EU following EUCERD Recommendations RARECARENet Project: Consensus meeting on.
High Resolution Studies within the European Cancer Information System Cooperation with EPAAC Riccardo Capocaccia Istituto Superiore di Sanità (ISS), Italy.
Work Package 5 Information on centres of expertise for rare cancers WP leader: Sabine Siesling.
A Phase II Study to Evaluate the Safety and Toxicity of Sparing Radiation to the Pathologic N0 Side of the Neck in Squamous Cell.
Work Package 2 Dissemination of the project RARECARENet Aidan Hutchison on behalf of Professor Ian Kunkler University of Edinburgh.
DISCUSSION. EUROCHIP-2 ACTION PLAN COUNTRY 1COUNTRY 2COUNTRY 3 COUNTRY 30 ACTION1ACTION1 ACTION2ACTION2 ACTION3ACTION3 ACTION3ACTION3 ACTION4ACTION4 ACTION4ACTION4.
Information network on rare cancers RARECARENet Annalisa Trama, Gemma Gatta Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (Italy)
1 "Cancer and the European Citizen – it’s time to deliver! Francesco De Lorenzo ECPC President ECPC Members in Action Conference 2009 ALL CANCER PATIENTS.
March 2001Management of Thyroid CancerInformation Projects Team THE MANAGEMENT OF PATIENTS WITH THYROID CANCER Cathy Bennett Information Projects Manager.
Statistics about unknown primary tumors Riccardo Capocaccia National Centre for Epidemiology, Surveillance and Health Promotion Istituto Superiore di Sanità,
Information network on rare cancers INFORMATION NETWORK ON RARE CANCERS (RARECARENet) Kick-off meeting - Friday, July Gemma Gatta Fondazione IRCCS,
Work Package 5 Objectives of the work shop Utrecht 17 th January 2014 Information on centres of expertise for rare cancers WP leader: Sabine Siesling.
EUROCHIP-2 EUROCHIP-2 - The Action Public Health Program EUROPEAN COMMISSION: HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL.
Organization and guideline development April 2010 ACCC The Netherlands.
Orphanet Europe State of the Art of Database and Services Polish activity Orphanet Europe State of the Art of Database and Services Polish.
Cancer Centers In Clinical Trials Sandrine Marreaud Head of Medical Department.
RARECARE project Data quality and supplementary information Granada, March 25 th 2009 Andalusian School of Public Health.
GENOMICS TO COMBAT RESISTANCE AGAINST ANTIBIOTICS IN COMMUNITY-ACQUIRED LRTI IN EUROPE (GRACE) H. Goossens (Coordinator), K. Loens (Manager), M. Ieven.
Work Package 5 The way forward Utrecht 17 th January 2014 Timeline for the High Resolution study Jan Maarten van der Zwan.
Information network on rare cancers Work Package 4 Information on epidemiology of rare cancers Riccardo Capocaccia and Sandra Mallone Cancer Epidemiology.
Cancer Outcomes and Services Dataset Linda Wintersgill Information & Audit Manager, NECN.
EUROCHIP-Italia in EUROCHIP-2 Health Indicators for Monitoring Cancer in Europe Public Health Program EUROPEAN COMMISSION: HEALTH & CONSUMER PROTECTION.
THE EFFECT OF AGE ON OUTCOME OF SYNOVIAL SARCOMA PATIENTS A DUTCH POPULATION BASED STUDY Myrella Vlenterie, SEJ Kaal, VKY Ho, R Vlenterie, WTA van der.
EUNetPaS is a project supported by a grant from the EAHC. The sole responsibility for the content of this presentation lies with the author(s). The EAHC.
National Cancer Intelligence Network Outcome and the effect of age in 1318 patients with synovial sarcoma: Report from the National Cancer Intelligence.
How clinicians use data to make an impact on clinical outcomes Andrew Brodbelt Consultant Neurosurgeon and Clinical Director of Neurosurgery, The Walton.
The Cancer Registry of Norway Jan F Nygård Head of the IT-department.
Where can I find data on cancer? Victoria H Coupland London Knowledge and Intelligence Team 20 February 2014.
Aim: Describe how new health care professionals are deployed
Overview of key findings from the MUNROS project
Breast Cancer Research in Pakistan
Patient Empowerment in Oncology Birgit BEGER, ECCO CEO
Discordance of histo-pathological diagnosis of patients with soft tissue sarcoma referred to tertiary care center. Rastogi,S., Aggarwal, A., Soti, K.,
WP 4 – EPIDEMIOLOGY GEMMA Gatta
JARC – Work Package 5 Assuring Quality of Care 12 month Report
The BAHNO Head & Neck Cancer Surveillance Audit 2018
Working Package 7 (WP7) Health Care
JARC General Assembly, Oct 16th, 2017
STEERING COMMITTEE MEETING
Oncology Market Forecast
National Oesophago-Gastric Cancer Audit 2018 Annual Report: Slide set
The BAHNO Head & Neck Cancer Surveillance Audit 2018
Regional radiotherapy and oncology network in SEE countries
The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.
Gender representation of board members in all international societies (reference year: 2016). Gender representation of board members in all international.
Megan Eguchi, MPh Sana karam, md, phd
General Assembly, 26th October, 2018, Milan
SYNOPSIS OF THE PROTOCOL
Presentation transcript:

Objectives of Work Package 5 objectives for today Information on centres of expertise for rare cancers WP leader: Sabine Siesling

Information network on rare cancers Work Package 5 Aim – To identify the qualification criteria for centres Centres of Expertise (CoE) for rare cancers Deliverable (No: 7) – Report identifying criteria indicating the level/quality of expertise for rare cancers management

Information network on rare cancers Milestones ‘Consensus’ meeting on criteria CoE (today) A protocol for the high resolution study Data collection (cancer registries) and analysis Meeting to discuss the results Final dissemination meeting with experts held/report > spring 2014

Information network on rare cancers How? with a wide consensus process high resolution studies feedback/discussion on the results Together with partners, collaborators, clinicians, patients, scientific societies, health authorities

Information network on rare cancers High resolution study Study with detailed data on i.e. stage and treatment Answering more in depth questions More than the “general” epidemiological / public health study questions (incidence, mortality, survival, prevalence) Possible already gathered in the cancer registry or available but still needs to be registered

Information network on rare cancers Partners WP5 Associated partner: INT, ISS, UEDIN, ECPC, NOH, NCR, CSF, OILJ Collaborating partners: RCE (Rare cancers Europe), EPAAC, ESSO, ESO, INSERM (Orphanet), Centre of Leon Bernard, ESMO, LeukaNet, ECCO – Experts (clinicians and patient groups) for selected tumour types!

Information network on rare cancers YOU!

Information network on rare cancers Criteria for CoE General criteria > all rare tumour types Specific criteria > selection of tumour types

Information network on rare cancers General criteria for CoE General criteria for CoE on all rare diseases available – European Union Committee of Experts of rare diseases (EUCERD) – Multidisciplinary scientific society – Patient organizations – Policy makers

Information network on rare cancers Possible general criteria for CoE (EUCERD): 1) the attractiveness measured through the volume of cases treated (relation to WP4), 2) the capacity to produce and adhere to clinical guidelines (i.e. staging procedure and treatment), 3) outcomes (i.e. surgical free margins, number of revision surgery, survival and recurrence),

Information network on rare cancers Possible general criteria for CoE (EUCERD): 4) the availability of multidisciplinary team, 5) the collaboration with other centers of expertise at national and international level (also for clinical trials). 6) capacity to participate in data collection (clinical research and public health in relation to CR)

Information network on rare cancers Only for a selection of rare cancer types Rationale: - Expected difference in clinical management (adherence to guidelines) - Expected difference in clinical outcome - Geographical patterns (risk factors) and trends in incidence - Already work done by other groups - Not extremely rare Specific criteria for CoE and High Resolution Studies

Information network on rare cancers Specific criteria for CoE and High Resolution Studies Four groups of rare tumours we focus on; 1. Sarcomas 2. Testicular cancer 3. Neuroendocrine tumours 4. Head And Neck Tumours

Information network on rare cancers Criteria for expert groups to develop specific indicators Develop tumour specific indicators for CoE on specific rare tumours preferably based on guidelines All experts involved in diagnostics and treatment for specific tumour Pathology, medical oncology, surgery, radiotherapy, patient advocacy groups

Information network on rare cancers Objectives of meeting today 1. A list of the main issues per tumour site 2. The way forward to come to indicators

Information network on rare cancers 1. A list of the main issues per tumor site Document circulated with proposal Presentation of key-note minutes – What is very important for this specific cancer? – Are there disparities to be expected between hospitals? – Can we identify centres of excellence with main issues? – Are there main issues lacking? – How is the view of the patient? - Proposal of most important issues?

Information network on rare cancers 2. The way forward to come to indicators - Continuation of todays meeting - High detailed analysis - Collaboration with other parties for dissemination of results - EORTC/OECI - Role of scientific society - Role of patients - Who else should be involved?

Information network on rare cancers Questions and suggestions